spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Sterling Pharma Solutions launches following management buyout

Sterling Pharma Solutions

New CDMO formed as a result of buyout of UK-based site

UK-based Sterling Pharma Solutions has formed as an independent contract development and manufacturing organisation (CDMO) following a management buyout (MBO) of the UK based Dudley site.

Formerly operating as Shasun Pharma Solutions within Strides Shasun, the process of divesting the business to the current management team was completed in September 2016.

Following the MBO, the newly divested business has been rebranded and launched as Sterling Pharma Solutions. The CDMO will specialise in delivering API development and manufacturing solutions to support global pharmaceutical companies across the entire product lifecycle.

The management team will be led by Kevin Cook as CEO. Kevin joined the Dudley site in 1993. He says: “We are delighted to complete the MBO and excited about building a global API services business with roots in the north east of England. Our offering is compelling as we can take projects from proof of concept to commercial scale manufacture all on one site. We also have the capabilities to handle the most hazardous chemical processes safely.

“We have experienced significant growth in the US and Europe in recent years and believe the extensive capabilities at our site, coupled with our heritage in the API services sector, provide us with an excellent foundation to become the leading partner and provider of API services to the pharmaceutical industry.”

Sterling Pharma Solutions’ site in Dudley, UK, has been in existence for 47 years and is the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry.
phone +44 (0) 191 250 0471
email enquiries@sterlingpsl.com
web www.sterlingpharmasolutions.com
email Sterling Place, Dudley Cramlington, Northumberland, NE23 7QG, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>


White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement